Literature DB >> 11037856

Successful cord blood transplantation for sickle cell anemia from a sibling who is human leukocyte antigen-identical: implications for comprehensive care.

L Gore1, P A Lane, R R Quinones, R H Giller.   

Abstract

We report the successful transplantation of umbilical cord blood stem cells from a sibling who is human leukocyte antigen-matched to a child with sickle cell anemia. Conditioning was with busulfan, cyclophosphamide, and antithymocyte globulin. Time to neutrophil count >500/microL was 23 days and to platelet count >50,000/microL was 49 days. Full donor engraftment was achieved without graft-versus-host disease. This case demonstrates the potential usefulness of harvesting cord blood from full siblings of patients with sickle cell disease. Routine collection of umbilical cord blood from siblings should be considered for patients with sickle cell disease, and may increase acceptance and use of transplantation by families.

Entities:  

Mesh:

Year:  2000        PMID: 11037856     DOI: 10.1097/00043426-200009000-00010

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia.

Authors:  Courtney D Fitzhugh; Mark C Walters
Journal:  Blood Adv       Date:  2017-12-08

Review 2.  Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.

Authors:  Courtney D Fitzhugh; Allistair A Abraham; John F Tisdale; Matthew M Hsieh
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-29       Impact factor: 3.722

Review 3.  Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.

Authors:  Matthew M Hsieh; Courtney D Fitzhugh; John F Tisdale
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

4.  Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.

Authors:  Sandhya Kharbanda; Angela R Smith; Stephanie K Hutchinson; David H McKenna; James B Ball; Lawrence S Lamb; Rajni Agarwal; Kenneth I Weinberg; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-24       Impact factor: 5.742

Review 5.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.